Some authors investigated the role of ANGPT2 variants in colorectal cancer patients with liver metastases [18] or in breast cancer patients [19] in relation to bevacizumab-based treatment, but no work has studied the impact of Ang-2 genetic variants in relation to treatment in HCC patients. This evidence concerns the gene ANGPT2 and breast carcinoma.